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EducationLevetiracetam(LEV) is a novel antiepileptic drug (AED) approved for the adjunctive treatment of generalized and
partial seizures. LEV has no clinically signiﬁcant drug interactions and has limited adverse effects. The psychiatric
adverse effects of LEV include de novo psychosis, affective disorder, and aggression. LEV-induced suicidal behavior
has been reported infrequently with a past history of affective disorders. The authors report an apparent dose/
concentration-dependent LEV-induced de novo major depression with near fatal suicide attempt in a patient
without prior history of affective disorder. Psychiatric evaluation with emphasis on historic/current affective
disorders, impulsive–aggressive behaviors, and assessment of risk factors for suicidal behaviors is indicated in
treating patients with epilepsy with LEV. Clinicians should consider therapeutic drug monitoring to optimize
therapeutic LEV treatment.
© 2013 The Authors. Published by Elsevier Inc.Open access under CC BY-NC-ND license.1. Introduction
Levetiracetam [(S)-alpha-ethyl-2-oxo-1-pyrrolidine acetamide] (LEV)
is a second generation anticonvulsant approved by the European
Medicines Agency (EMA) and/or the U.S. Food and Drug Administration
(FDA) for the following: 1) monotherapy treatment of partial seizures,
with or without secondary generalization (EMA); 2) adjunctive treat-
ment of partial seizures, with or without secondary generalization
(FDA/EMA); 3) adjunctive treatment of myoclonic seizures associated
with juvenile myoclonic epilepsy (FDA/EMA); and 4) adjunctive
treatment of primary generalized tonic–clonic seizures associated
with idiopathic generalized epilepsy (FDA/EMA) [1,2]. LEV uniquelyongress, Montreal, Canada, June
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.Open access under CC BY-NC-ND licenbinds to synaptic vesicle protein 2A (SV2A) with resultant broad spec-
trum anticonvulsant activity [3,4].
LEV has no clinically signiﬁcant pharmacokinetic drug interactions
[5]. A review of clinical trials demonstrated that LEV was well tolerated
with limited psychiatric adverse effects [6]. LEV-induced psychiatric ad-
verse effects are not dose-dependent [7,8]. Improved depression and
anxiety have been reported in patients with epilepsy treated with LEV
[9]. A recent study suggested that LEV is cognitively benign [10]. The
pharmacokinetic, tolerability, psychiatric, and neuropsychological
proﬁles of LEV have led to it being studied for the off-label treatment of
neurologic disorders (Parkinson's disease, Huntington's disease, tardive
dyskinesia, dystonia, multiple sclerosis), psychiatric disorders (bipolar
disorder, panic disorder, posttraumatic stress disorder, social anxiety,
impulsive aggression, alcohol dependence, alcohol withdrawal, behav-
ioral and psychological symptoms of dementia), and pain disorders
(migraine and neuropathic) with mixed results [11,12].
LEV-emergent suicidal behaviors (ideation and attempt) have been
infrequently reported [6,13]. In two studies, all suicidal behaviors
were associated with a previous history of psychiatric disorders
[13,14]. This case report presents what the authors believe to be the
ﬁrst instance of dose/concentration-dependent LEV-induced de novo
major depression with a near fatal suicide attempt following dosese.
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term stability on LEV.
2. Method
Case analysis with PUBMED literature review was employed.
3. Case
A 66-year-old male with diabetes, diabetic neuropathy, hypertension,
and past alcohol dependence with withdrawal features had two seizures
following a traumatic brain injury with an intracranial hemorrhage in
2007. He remained seizure-free on LEV 500 mg total daily dose until
being admitted to an academic medical center (AMC) on 4/22/2012
with elevated CPK (1731 U/l), hyperglycemia (428 mg/dl), hypocalcemia
(6.9 mg/dl), anemia (hemoglobin: 11.6 g/dl, hematocrit: 34.2%), and an
undetectable blood alcohol level. His admission LEV blood level was
10.9 μg/ml. Routine EEG was normal, and head MRI/CT revealed central
and cortical atrophy, moderate small vessel ischemic disease, and old bi-
lateral basal ganglia and right thalamic lacunar infarcts. Hewasmedically
stabilized and discharged on LEV 500 mg bid only to be readmitted on
8/3/2012 for recurrent seizures following LEVnoncompliance for oneweek.
Speciﬁcally, the patient ran out of his AED pending a mail-order
prescription. His wife (a health-care professional) witnessed a tonic-
clonic seizure of N3 min in durationwith postictal alteredmental status.
In the ER, the medical staff witnessed a further tonic-clonic seizure of
90 s in duration for which the patient received lorazepam 4 mg IV and
phenytoin 1000 mg IV. Admission laboratories and diagnostics included
the following abnormal results — LEV blood level: b2.0 μg/ml, WBC:
13.6, hemoglobin: 11.7 g/dl, hematocrit: 35.5%, glucose: 426 mg/dl,
sodium: 130 mEq/l, potassium: 2.5 mEq/l, chloride: 97 mEq/l, total
CO2: 20.3 mEq/l, magnesium: 1.3 mg/dl, HgbA1c: 11.9%, unchanged
CT scan ﬁndings, and EKG with ﬁst degree AV block and prolonged
QTc of 505 ms. Blood alcohol level and urine drug screenwere negative.
LEVwas increased to 1000 mg bidwith a subsequent LEV blood level of
32.9 μg/ml. A routine EEG with photic stimulation performed 3 days
after the presenting seizures revealed left temporal focal slowing
(theta and delta activity) without epileptiform discharges. The patient
remained without further seizures on the increased LEV, his postictal
state cleared, and after medical stabilization, he was discharged to the
home setting on LEV 1000 mg bid.
Prior to LEV being increased to 1000 mg bid, this patient had no his-
tory of psychopathology excluding alcohol dependencewithwithdraw-
al seizures. After LEV was increased to 1000 mg bid, the wife described
the patient discussing suicide and stating “life is not worth living.”
Within onemonth, he developed a complete vegetative–affective cluster
consistent with a de novomajor depressive episode according to DSM-IV
criteria [15], attempted a nearly fatal insulin overdose (80 units) with
ﬁeld glucose of only 1mg/dl, and was seen in psychiatric consultation
after admission to the same AMC. Admission laboratories included the
following abnormal results — hemoglobin: 12.0 g/dl, hematocrit: 35.4%,
potassium: 2.8 mEq/l, calcium: 8.3 mg/dl, magnesium: 1.3 mg/dl, and
HgbA1c: 10.6%. His alcohol blood level was 24.6 mg/dl with urine drug
screen, salicylate level, and acetaminophen level all negative. His admis-
sion LEV blood level was 38.9 μg/ml. A routine EEG with photic stimula-
tion performed on the day of admission revealed mild, infrequent,
independent, bilateral frontotemporal polymorphic delta activity with-
out epileptiform discharges. Upon medical stabilization, discontinuation
of LEV, and initiation of oxcarbazepine 300 mg bid, the patient was
transferred to an inpatient psychiatric unit and lost to follow-up.
4. Discussion
This unique case raises a series of important points speciﬁcally related
to this patient that should be considered in the general treatment of
patients with LEV and other AEDs.First, though LEV-induced psychiatric adverse effects are not consid-
ered to be dose-related [7,8], this case suggests that dose-dependence
may be a signiﬁcant factor in developing affective disorders with suicidal
behaviors. The patient did not have any psychiatric features during a ﬁve-
year period on LEV 500 mg total daily dose with a mildly subtherapeutic
blood level. Even with LEV increased to 1000 mg total daily dose, there
were no psychiatric features. With LEV increased to 2000 mg total daily
dose and a high therapeutic blood level, the patient developed a de novo
major depression and attempted a nearly fatal insulin overdose within
one month of dose titration.
Second, AED therapeutic drug monitoring with reference range and
individual therapeutic range is important in the optimal clinical treatment
of patientswith epilepsy [16]. As there is aminimal andoptimal threshold
concentration for AED efﬁcacy, this case suggests that the development of
adverse events for speciﬁc AEDs may also require a threshold concentra-
tion which can be within the reference range (LEV: 12–46 μg/ml).
Third, literature addressing suicidal behavior associated with AEDs
in patients with epilepsy has focused on the signiﬁcant increased risk
of this behavior when there is a prior history of affective disorder
[13,14,17]. This case clearly points out that an apparent LEV-induced
major depression with suicidal behavior may occur in the absence of
prior affective disorder. This is consistent with a recent study that did
notﬁndpsychiatric history to be a signiﬁcant predictor of either positive
or negative LEV-induced psychotropic effects [8].
Fourth, the 2008 FDA advisory that AEDs are associated with signif-
icantly increased suicidal behaviors resulted in a series of studies
attempting to address AED-speciﬁc suicidal behavior risk [18–20].
Conﬂicting ﬁndings from these studies are considered to be secondary
to ﬂaws in methodology, speciﬁcally controlling for prior suicidal
behavior [20]. This suggests the need for appropriate psychiatric assess-
ments in all patients treated with AEDs such that meaningful data can
be obtained. This also supports the need for detailed case reports
when suicidal behavior occurs following initiation of AED treatment
[19]. In this case, there was no pre-LEV history of psychiatric illness,
impulsive–aggressive behaviors, or suicidal behaviors excluding past
alcohol dependence.
Fifth, though the clinical trials revealed limited behavioral adverse
effects [6], more recent studies emphasized aggressive behavior as an
important negative psychotropic effect that may require LEV discontin-
uation [8,21,22]. This patient did not have any aggressive behaviors on
long-term LEV 500 mg total daily dose or when increased to 1000 mg
total daily dose, but rather the suicide attempt occurred at 2000 mg
total daily dose.
Sixth, a clinical model of suicidal behavior suggests that suicide is an
impulsive–aggressive act and that a critical risk factor for suicide is in-
creased impulsive–aggressive trait with familial/genetic transmission
of impulsive–aggressive trait correlating to an increased suicide risk
independent of psychopathology [23]. Literature supports genetic
neurotransmitter variants as etiological factors for impulsivity, suicidal
behavior, alcoholism, and aggression [23,24]. A recent study reported
an association between dopamine genetic variants and LEV aggression
[25]. Though no genetic data are available for this patient, suicidal
behaviors with AEDs may be associated with a genetic predisposition
independent of known psychiatric illness.
Seventh, recent literature supports a bidirectional relationship
among epilepsy, psychiatric disorders, and suicidality [26,27]. Though
this case describes a clear temporal relationship between LEVdose titra-
tion and de novomajor depressive episodewith suicide attempt, the po-
tential for epilepsy being the causative or predisposing factor must be
considered. Further potential risk factors for the development of major
depression and/or suicidal behaviors present in this case included
basal ganglia and thalamic lacunar infarcts, traumatic brain injury
with intracranial hemorrhage, and past alcohol dependence [23,28,29].
Eighth, in the context of multiple potential risk factors for the devel-
opment of de novo major depression with suicide attempt (epilepsy,
treatment with AED, LEV titration, past alcohol dependence, traumatic
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lacunar infarcts, and potential genetic predisposition), the probability
of LEV titration inducing the de novomajor depression with associated
near fatal suicide attempt was determined by the Naranjo's Adverse
Reaction Probability Scale as probable (scored as 5) [30].
There are speciﬁc limitations to this paper. As a case report (N = 1),
the ﬁndings cannot be generalized. The patient did not have any psychi-
atric assessment done prior to and following the traumatic brain injury
and initiation of LEV to assess general psychopathology, affective disor-
ders, and, speciﬁcally, impulsive aggression. Neuroimaging studies and
initial EEGs following the 2007 seizures were not available for compar-
ison. LEV blood level was not obtained when the patient was on
1000 mg total daily dose. Standardized psychometric scales for depres-
sion and impulsive aggression were not obtained. For ethical reasons,
the patient could not be rechallenged with LEV 2000 mg total daily
dose. Finally, the patient was lost to clinical follow-up precluding deter-
mination of recurrent impulsive-aggressive behaviors or affective fea-
tures after discontinuation of LEV.
5. Conclusions
LEV-induced suicidal behavior is an infrequent adverse effect noted
in patients with a prior history of affective disorder. The authors report
an apparent dose/concentration-dependent LEV-induced de novomajor
depressive episode with near fatal suicidal attempt in the absence of
prior affective history following chronic stable treatmentwith LEV. Clini-
cians should monitor affective features when treating patients with epi-
lepsy with LEV and other AEDs, be cognizant of other potential additive
risk factors for suicidal behaviors, and consider therapeutic drug moni-
toring to optimize therapeutic treatment. Further studies are required
to address dose/concentration-dependent LEV-induced psychiatric ad-
verse effects.
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